Boston Scientific completes acquisition of BTG

Boston Scientific announced thursday that it has completed its acquisition of BTG under a previously announced restructuring plan. BTG primarily develops and sells minimally invascopic surgery for cancer and vascular diseases, as well as special drugs.BTG has three core businesses, the largest of which is its highly differentiated portfolio of interventional medicine products, including tumor interventional therapy techniques for the treatment of patients with liver and kidney cancer, as well as a combination of vascular disease treatment techniques for the treatment of deep vein embolism, pulmonary embolism, deep vein obstruction and shallow vein diseases."The addition of BTG's portfolio of interventional medicines strengthens our leading strategy in product segmentation, enabling us to provide best-in-class technology, clinical evidence, and a better business infrastructure to support physicians in treating some of the most challenging diseases affecting patient health around the world," said Hongming Ma, President and CEO ofBoston Scientific. By combining the talents and clinical and business expertise of our two best companies, we will be able to achieve continuous innovation and healthcare coverage to develop disease treatment technologies in a way that no single company can. inaddition to its involvement in the medical product line, BTG's business portfolio includes the Special Medicines business, which includes acute therapeutic antidotes for the overexposition of certain drugs and toxins, and licensing businesses that collect usage fees related to BTG's intellectual property rights and product licensing agreements.BTG had become a wholly owned subsidiary of Boston Scientific when the restructuring took effect and BTG's shares were no longer traded on the London Stock Exchange. Under the terms of the previously announced deal, BTG common equity holders would earn 840p per share.Boston Scientific expects to complete its previously announced plan to sell its global embolism microchiw portfolio, which includes the Embozene, Embozene TANDEM and ONCOZENE brands, to Valian Medical Systems in due course. The transaction was made to pass the antitrust approval required to complete the BTG acquisition.addition, Boston Scientific is launching and researching the divestiture of its usage fee business related to BTG's Zytiga license agreement, which is expected to be completed by the end of 2019. (U.S. News Agency)